Currently, IGM Biosciences Inc [IGMS] is trading at $1.22, up 2.52%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IGMS shares have gain 15.09% over the last week, with a monthly amount drifted -3.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IGM Biosciences Inc [NASDAQ: IGMS] stock has seen the most recent analyst activity on January 10, 2025, when Stifel downgraded its rating to a Hold and also revised its price target to $2.50 from $27. Previously, RBC Capital Mkts downgraded its rating to Sector Perform on January 10, 2025, and dropped its price target to $1.50. On January 10, 2025, downgrade downgraded it’s rating to Underweight and revised its price target to $2 on the stock. Guggenheim downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2 on January 10, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on December 06, 2024, and assigned it a price target of $21. In a note dated October 01, 2024, Truist downgraded an Hold rating on this stock and revised its target price from $24 to $12.
This stock has fluctuated between a low of $0.92 and a high of $22.50 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $8.17 within the next 12 months. IGM Biosciences Inc [NASDAQ: IGMS] shares were valued at $1.22 at the most recent close of the market. An investor can expect a potential return of 569.67% based on the average IGMS price forecast.
Analyzing the IGMS fundamentals
Trailing Twelve Months sales for IGM Biosciences Inc [NASDAQ:IGMS] were 2.68M which represents -36.71% decline. Gross Profit Margin for this corporation currently stands at -0.66% with Operating Profit Margin at -77.86%, Pretax Profit Margin comes in at -73.09%, and Net Profit Margin reading is -73.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is -1.91 and Total Capital is -0.91. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1767 points at the first support level, and at 1.1333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.2567, and for the 2nd resistance point, it is at 1.2933.
Ratios To Look Out For
To put it in perspective, the Current Ratio for IGM Biosciences Inc [NASDAQ:IGMS] is 5.14. Also, the Quick Ratio is 5.14, while the Cash Ratio stands at 0.7. Considering the valuation of this stock, the price to sales ratio is 27.21, the price to book ratio is 1.51.
Transactions by insiders
Recent insider trading involved Weber Steven, PRINCIPAL ACCOUNTING OFFICER, that happened on Mar 14 ’25 when 1701.0 shares were sold. CHIEF FINANCIAL OFFICER, Tahir Misbah completed a deal on Mar 14 ’25 to sell 7329.0 shares. Meanwhile, Chief Executive Officer Harler Mary Beth sold 7329.0 shares on Mar 14 ’25.
